Discover 127 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 127
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Billings MT, Pierre SD, Spokane WA, Aberdeen SD,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT05947851
Phase 3, Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for
Diffuse Large B-Cell Lymphoma
Location: Billings MT, Golden CO, Fargo ND, Edmonton,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06717347
Phase 3, Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for
Metastatic Castration-resistant Prostate Cancer (mCRPC),
Location: Billings MT, Pierre SD, Spokane WA, Lakewood CO,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06136650
Phase 3, Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
for
Ovarian Cancer
Location: Billings MT, Salt Lake City UT, Sioux Falls SD,
Sponsor: Daiichi Sankyo
Sex: Female
Age: 18+
Code: NCT06819007
Phase 3, Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer